Business
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and ExpansionLOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhur
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"Turn Therapeutics","displaySize":"","headline":null,"caption":"Turn Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uTv2v5jICXhGET5aPRSD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39","width":300,"height":101}},"lazy":false},{"type":"text","content":"Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion","length":166,"tagName":"p"},{"type":"text","content":"LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases, announced today the appointment of Mr. Martin Dewhurst to its Board of Directors. Mr. Dewhurst brings more than 30 years of global leadership experience in life sciences, with a particular focus on mergers and acquisitions.","length":469,"tagName":"p"},{"type":"text","content":"“Martin’s appointment comes at a pivotal moment for Turn Therapeutics as we advance a disciplined, M&A-focused strategy to expand our pipeline and accelerate long-term value creation,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “Martin brings a unique strategic lens to capital allocation, portfolio expansion, and partnership development stemming from his deep experience as a leader in the life sciences industry. His insights will be instrumental as we evaluate accretive opportunities that complement our platform and position Turn for sustainable growth.”","length":588,"tagName":"p"},{"type":"text","content":"Mr. Dewhurst dedicated much of his three-decade career to McKinsey & Company, where he co-led the firm’s global life sciences practice. His expertise encompasses biopharmaceuticals, medical technology, genetics, and consumer health. Most recently, he co-founded and led the McKinsey Health Institute, a nonprofit organization focused on tackling some of the world’s most pressing health challenges.","length":402,"tagName":"p"},{"type":"text","conte...